CD22 and acute lymphoblastic leukemia: CD22 APC expression (that was added as an additional marker panel in two precursor B-ALL cases to demonstrate that the addition was possible) was verified against the expected disease outcome (positive in two cases of B-ALL) and met the manufacturer’s specifications in the DURAClone RE ALB (Table 3).